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Introduction
From its origins with the first successful 
transplant of banked cadaveric tissue 
in the first half of the 20th century, the 
transplantation of human tissues (HTs) 
has become a widely practised surgical 
procedure.1 Today, HTs are transplanted 
across the globe not only to save lives, 
but also to improve lives through recon-
structive and cosmetic interventions. 
Due to the growing demand for HTs 
and the increasing quality and safety 
standards required in tissue banking, 
many of the original hospital-based tis-
sue banks, designed to meet local needs, 
have been replaced by national or mul-
tinational HT organizations which sell 
their products internationally and may 
operate on a for-profit basis.
In parallel, the transplantation of 
human cells (HCs) – haematopoietic 
progenitor cells in particular – has 
evolved into a widely used clinical ac-
tivity. After the first successful bone 
marrow transplants in the 1960s, sub-
sequent advances in immunosuppres-
sive and antibiotic therapy have made 
haematopoietic progenitor cell trans-
plantation an established treatment for 
Abstract The transplantation of human cells and tissues has become a global enterprise for both life-saving and life-enhancing 
purposes. Yet current practices raise numerous ethical and policy issues relating to informed consent for donation, profit-making, 
and quality and safety in the procurement, processing, distribution, and international circulation of human cells and tissues. This 
paper reports on recent developments in the international debate surrounding these issues, and in particular on the attention 
cell and tissue transplantation has received in WHO’s ongoing process of updating its 1991 Guiding principles on human organ 
transplantation. Several of the organizers of an international working group of stakeholders from a wide range of backgrounds 
that convened in Zurich in July 2006 summarize the areas of normative agreement and disagreement, and identify open questions 
regarding facts and fundamental concepts of potential normative significance. These issues must be addressed through development 
of common medical, scientific, legal and ethical requirements for human cell and tissue transplantation on a global basis. While 
guidance must accommodate the distinct ethical issues raised by activities involving human cells and tissues, consistency with 
normative frameworks for organ transplantation remains a prime objective.
Bulletin of the World Health Organization 2007;85:941–948.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
International perspectives on the ethics and regulation of 
human cell and tissue transplantation
Annette Schulz-Baldes,a Nikola Biller-Andorno a & Alexander Morgan Capron b
الرتجمة العربية لهذه الخالصة يف نهاية النص الكامل لهذه املقالة.
a  Institute of Biomedical Ethics, Center for Ethics, University of Zurich, Zollikerstr. 115, 8008 Zurich, Switzerland. Correspondence to Annette Schulz-Baldes (e-mail: 
schulz-baldes@ethik.uzh.ch).
b  Gould School of Law, University of Southern California, Los Angeles, CA, United States of America.
doi: 10.2471/BLT.06.038703
(Submitted: 10 November 2006 – Revised version received: 3 July 2007 – Accepted: 15 July 2007 )
a wide variety of genetic and malignant 
diseases.2 As with HT, haematopoietic 
progenitor cells are exchanged globally 
today,3 driven by the need to find a 
donor that closely matches the human 
leucocyte antigen type of the recipient. 
Profit-making has also been introduced 
into the field with the establishment 
of for-profit (private) autologous cord 
blood banks and a growing number of 
clinics offering experimental cell trans-
plants.4,5
Current practices in HC/HT trans-
plantation raise several questions that 
need to be addressed jointly by clini-
cians, scientists, health regulators and 
ethicists as well as representatives of civil 
society, in particular HC/HT donors 
and recipients. The increasing com-
mercialization of HC/HT products 
has multiplied opportunities for profit- 
making and increased the risk of clini-
cally unsafe and unethical practices 
(particularly in HT procurement). 
Recent scandals in the United States 
of America 6,7 and other countries 8,9 
involving nonconsented procurement 
underline the urgent need for a com-
mon global technical and ethical frame-
work. Although a number of regulations 
on HC/HT transplantation have been 
adopted in the past several years or are 
currently under discussion,10–12 national 
regulation and oversight of HC/HT 
transplantation is nonexistent or inef-
ficient in many countries.
Moreover, regulation is no longer 
merely a national matter because HCs/
HTs can be processed, preserved and 
easily transported around the globe. 
While the international circulation of 
HCs/HTs can facilitate access, it can 
also spread tainted material, create global 
inequities in donation or accentuate 
inequities in access to HC/HT services. 
The lack of ethical guidance and the ex-
istence of unmonitored or unregulated 
HC/HT procurement and distribution 
represent a serious international risk to 
both donors and recipients of cells and 
tissues.
WHO has given special attention 
to human cell and tissue transplanta-
tion in the process of updating its 
1991 Guiding principles on human organ 
transplantation,13 an activity which has 
been ongoing since 2004.14 As part 
of this process, WHO’s Departments 
of Essential Health Technologies and 
Ethics, Trade, Human Rights and 
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Health Law held a meeting jointly 
with the Institute of Biomedical Ethics, 
University of Zurich, in July 2006. The 
meeting involved an international group 
of experts on transplantation medicine, 
nursing, ethics, social sciences, law and 
policy-making. Meeting participants 
were: Tsuyoshi Awaya (Okayama Uni-
versity, Japan), Nikola Biller-Andorno 
(University of Zurich, Switzerland), 
Arlinke Bokhorst (Bio Implant Services, 
Leiden, Netherlands), Alexander Capron 
(WHO, Geneva, Switzerland), Mar 
Carmona (WHO, Geneva, Switzerland), 
Francis Delmonico (Transplantation 
Society, Boston, MA, United States), 
Deirdre Fehily (Centro Nazionale Tra-
pianti, Rome, Italy), Gregorio Garrido 
Cantarero (Organización Nacional 
de Trasplantes, Madrid, Spain), Jens 
Gobrecht (WHO, Geneva, Switzer-
land), Alois Gratwohl (University of 
Basel, Switzerland), Bernadette Haase- 
Kromwijk (Dutch Transplant Founda-
tion, Leiden, Netherlands), Marisa 
Herson (Asociacion Latinoamericana 
de Bancos de Tejidos, Sao Paulo, Brazil), 
Roman Hitchev (Osteocentre Bulgaria 
EAD, Sofia, Bulgaria), Liisa Kok (Dutch 
Ministry of Health, Netherlands), Jan 
Koller (Central Tissue Bank, Bratislava, 
Slovakia), Theo Le Roux (University of 
Pretoria National Tissue Bank, South Af-
rica), Nabila Metwalli (WHO EMRO, 
Cairo, Egypt), Conrad Müller (Swis-
stransplant, Berne, Switzerland), Ales-
sandro Nanni Costa (Centro Nazionale 
Trapianti, Rome, Italy), Aziz Nather 
(National University of Singapore, 
Singapore), Luc Noel (WHO, Geneva, 
Switzerland), Jan Pierce (American As-
sociation of Tissue Banks, McLean, 
VA, United States), Virender Sangwan 
(LV Prasad Eye Institute, Hyderabad, 
India), Volker Schmidt (National Uni-
versity of Singapore, Singapore), Annette 
Schulz-Baldes (University of Zurich, 
Switzerland), Naoshi Shinozaki (Cornea 
Center, Ichikawa, Japan), Magi Sque 
(University of Southampton, United 
Kingdom), Caroline Trouet (Euro-
pean Commission, Brussels, Belgium), 
Yongyudh Vajaradul (Siriraj Hospital, 
Bangkok, Thailand), Rüdiger von 
Versen (German Institute for Cell and 
Tissue Replacement, Berlin, Germany) 
and Kathryn Wood (Transplantation 
Society, Oxford, United Kingdom). The 
meeting focused on tissues – notably 
bone, skin, tendon and fascia as well as 
cornea, pericardium, heart valves, arteries 
and veins, procured for clinical use from 
deceased persons – and haematopoietic 
stem cells from cord blood and adult 
living donors. Issues relating to HCs/
HTs retained for research or education 
purposes, HCs/HTs from human em-
bryos or from animals, human blood or 
blood products and human reproductive 
cells, such as oocytes and spermatocytes, 
were not addressed.
The aim of the meeting was to 
delineate areas of normative consensus 
and divergence about HC/HT trans-
plantation. Drawing on the Reflection 
Document that resulted from the meet-
ing,15 this paper provides the perspective 
of several of the meeting’s organizers 
on the agreements and disagreements 
among stakeholders that emerged re-
garding normative issues, as well as facts 
and fundamental concepts of potential 
normative significance.
Current ethical and policy 
issues in HC/HT transplanta-
tion – areas of agreement 
and disagreement
1. Consent for removal of human 
cells and tissues
In line with universal ethical principles, 
the meeting participants agreed that in-
formed consent was necessary whenever 
obtaining human cells and tissues. With 
regard to living donors, this conclusion 
was unambiguous: HCs/HTs should 
only be procured after the donor has 
given informed and voluntary consent, 
or, in rare cases when a minor is a donor 
of haematopoietic progenitor cells to a 
close relative, a surrogate has consented 
and the minor has assented after careful 
deliberation and professional scrutiny. 
While donors should be able to with-
draw consent at any time before actual 
procurement, withdrawal can be highly 
problematic when, for example, the re-
cipient is already immunosuppressed for 
transplantation of haematopoietic pro-
genitor cells. This should be made clear 
to the donor at the time of consent.
Yet consent in and of itself was not 
considered sufficient to justify HC/HT 
procurement from living donors which 
can cause serious, even irreversible harm. 
Participants therefore agreed that live 
HC/HT donation should not be prac-
tised unless there is no feasible alterna-
tive and means are in place to effectively 
protect the donor’s health and safety.
The implications for deceased HT 
donation were less straightforward. Sub-
stantial normative disagreement existed 
about whether presumed consent is 
ethically equivalent to actual informed 
consent, mirroring the longstanding de-
bate regarding consent for post-mortem 
organ donation. However, participants 
broadly agreed concerning the practical 
challenges of presumed consent systems; 
namely, how to conduct public debates, 
to verify a positive societal attitude 
towards donation and to incorporate 
suitable measures for continued public 
education about the donation process, 
its implications and the procedures for 
individuals to opt out.
Meeting participants also agreed 
that, irrespective of the consent scheme, 
bereaved next of kin or legal representa-
tives must be approached by specially 
trained professionals who are compe-
tent in sensitively discussing deceased 
HT donation (including the donor’s 
history) and providing follow-up sup-
port. As far as possible, participants 
thought the information given in the 
donation discussion should reflect the 
informational needs of the consenting 
party. The exact amount and depth of 
information, however, were contentious. 
Because information about the proce-
dures of HC/HT activities is complex 
and continuously changing, requiring 
fully-informed consent from an emo-
tionally distressed person seemed overly 
arduous to some. It was particularly con-
troversial whether information should 
be provided that relates to whether the 
processing or distribution of cells or tis-
sues would produce a profit or surplus. 
Some suggested a nuanced approach 
that would require informing the next 
of kin or legal representatives only if 
the institutions involved in HC/HT 
processing or distribution dispense 
profits among owners or shareholders. 
Views also varied on the need to inform 
about the possibility that donated cells 
or tissues would be used abroad or for 
cosmetic purposes. Yet all participants 
concurred that consent cannot be valid 
if the consenting party is deceived or 
donates under false assumptions.
Mirroring ongoing debates about 
procurement of organs, participants also 
disagreed about whether next of kin should 
be allowed to veto the choice a person had 
made to donate tissue after death or, in a 
presumed consent system, the donation 
that would occur when the deceased had 
not opted out. Some meeting participants 
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argued that, to increase donation rates, 
the wishes of designated donors should 
be respected even if the next of kin object. 
Others asserted that doing so would be 
unacceptable, particularly in societies 
where family ties are strong.
2. Confidentiality of donor data
Confidentiality of donor data was con-
sidered a requirement for all activities 
involving HCs/HTs. However, par-
ticipants acknowledged exceptions in 
the case of testing results which indicate 
a high risk of serious and preventable 
harm to third parties and agreed that 
donors or next of kin should be informed 
accordingly in the donation discussion. 
Ideally, consent should be sought for 
disclosing results which indicate a condi-
tion that cannot be treated due to resource 
constraints (e.g. anti-retroviral treatment 
in resource-poor countries).
3. Unpaid donation
By analogy to organ donation, all meet-
ing participants concurred that dona-
tion of cells and tissues should remain 
unpaid, because payment can unduly 
induce vulnerable and poor living do-
nors or constitute a conflict of interest 
for next of kin or legal representatives in 
deceased donation, and is likely to result 
in inequities in donation. Some also 
worried that paying for cells or tissues 
increases the likelihood of inaccurate 
responses on donor-history question-
naires, resulting in transplanted materi-
als carrying an undetected disease. At 
the same time, the need to remove 
financial disincentives for HC/HT 
donation was recognized as it has been 
for organ donation. Participants there-
fore concluded that only compensation 
for travel expenses, loss of earnings 
or other expenses actually incurred in 
donation may be allowed and must be 
transparent and regularly audited. Gen-
eral consensus also existed that for-profit 
organizations should not be involved in 
promoting cell and tissue donation, or 
discussing it with potential donors, to 
avoid conflicts of interest.
More generally, although HC/HT 
procurement and transplantation have 
become quite common, the fundamen-
tal legal, economic and philosophical 
concepts of “body ownership” remain 
surprisingly vague for both living and 
deceased persons. This is startling con-
sidering that fundamental agreed norms 
about ownership are a general precondi-
tion for ordinary transactions. The lack 
of an overarching concept of body own-
ership also has practical implications 
because legal and regulatory definitions 
of human cells and human tissues re-
main to some extent arbitrary, although 
they heavily influence practices.
4. Fair procurement of cells and 
tissues
There was broad agreement that do-
nors should be identified and selected 
according to fair and explicit criteria, 
above all medical eligibility, equally and 
without explicit or implicit discrimi-
nation based on social status, race or 
gender. Meeting participants recognized 
that the geographical location of HC/
HT procurement facilities inevitably 
affects procurement where donation 
programmes are not well developed and 
resources are limited. There was also 
broad agreement that consent proce-
dures and the methods for approaching 
potential donors should be standard-
ized, transparent and subject to regular 
external auditing, given that vulnerable 
groups are at risk for subtle or overt 
manipulation regarding the decision to 
donate HCs/HTs.
A controversial issue was how tis-
sue and organ procurement should be 
coordinated in those deceased donors 
who are medically suitable to donate 
both organs and HCs/HTs. Some par-
ticipants believed that profit-making 
opportunities could bias in favour of 
procuring HTs rather than organs (e.g. 
heart valves instead of the entire heart), 
whereas others regarded such scenarios 
as practically irrelevant. Yet all partici-
pants recognized the need to coordinate 
procurement, while supporting the gen-
eral priority of procuring organs over 
HTs, if clinically appropriate, because 
of the greater scarcity of organs and 
because organs are more frequently used 
for life-saving purposes. Nonetheless, 
disagreement remained whether this 
priority should be binding.
5. Stewardship for donated cells 
and tissues
All meeting participants agreed that HC/
HT organizations have a responsibil-
ity to act as stewards of the donations 
entrusted to them for the benefits of 
others. Most participants concurred that 
HC/HT activities should, to the extent 
possible, fulfil the intentions or expecta-
tions expressed in the consent to donate 
regarding the future clinical, research and 
educational uses of donated HCs/HTs, 
the making of profit from the processing 
and distribution of the cells and tissues, 
and their circulation outside the country. 
Consensus existed that donors or next 
of kin should be given the opportunity 
to veto future HC/HT use for research, 
education and training. However, not all 
meeting participants supported the right 
to veto HC/HT circulation abroad or use 
for cosmetic purposes because of the prac-
tical difficulties in implementing such 
requests and the concern that including 
full information about such choices may 
be too complex or too emotionally bur-
densome for bereaved relatives or other 
legal representatives. Yet all concurred 
that procurement organizations should 
not implement donors’ instructions to 
discriminate against individual recipi-
ents, in particular on racial or religious 
grounds.
Participants also endorsed that, 
in addition to respecting the non- 
discriminatory wishes of individual do-
nors, HC/HT institutions and the profes-
sion should set priorities for clinical uses 
of HCs/HTs in light of their compatibil-
ity with general donor intent. However, 
even this common perspective did not 
yield straightforward conclusions. For ex-
ample, it remained problematic whether 
HC/HT use for cosmetic purposes should 
be rigorously rejected, given that the 
distinction between reconstructive and 
cosmetic interventions is not clear-cut 
and a decline in certain preparations that 
can be used for both reconstructive and 
cosmetic purposes could imperil the care 
of patients in need.
Meeting participants found it overly 
simplistic to frame stewardship by con-
trasting for-profit with not-for-profit 
organizations. For one thing, what it 
means for an organization to be “for-
profit” is, in many cases, unclear, and 
“profit-making” is a descriptive, not an 
inherently moral attribute. All organiza-
tions that process or distribute HCs/HTs 
can produce a surplus of income over 
expense, but the framework for using 
this surplus differs. Not-for-profit orga-
nizations are, at least in theory, subject 
to rules that tightly control the extent to 
which individuals may receive financial 
and material benefits; accordingly, sur-
pluses must be used in ways consistent 
with the organization’s purpose, such as 
in improving HC/HT services or sup-
porting other services when the HC/HT 
activity is a unit within a publicly funded 
health system. In for-profit organiza-
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tions, in contrast, surpluses that are not 
reinvested are distributed among the 
owners (such as the shareholders of cor-
porations) and/or lead to higher salaries 
for the managers.
However, the apparent distinction 
between for-profit and not-for-profit 
institutions is often blurred in practice. 
Not-for-profit institutions may own or 
collaborate with for-profit subsidiaries,16 
and in countries where HC/HT orga-
nizations do not receive public funding, 
patients may have to rely on services of 
for-profit institutions to access neces-
sary medical care. Furthermore, for- 
profit organizations are sometimes in a 
better position to invest in high-quality 
facilities and/or research and develop-
ment, and may thereby promote ef-
ficient use of donated HCs/HTs and 
improvement of services. This can help 
to ensure enhanced benefits from the 
donation for patients, which is also an 
ethical imperative.
Finally, the institutional structure 
itself does not indicate the amount of 
income. For-profit institutions can gen-
erate little profit, while not-for-profit 
institutions can have large surpluses. 
What matters from a normative per-
spective is the way income is managed 
and the effects that efforts to generate 
surplus revenues have on stewardship, 
efficiency, transparency, accountability, 
fair pricing, responsiveness to local or 
national health needs and fair alloca-
tion. These criteria are more important 
in evaluating HC/HT organizations 
normatively than their formal profit-
making status.
All participants recognized that be-
ing operated on a for-profit basis can 
create conflicts of interest or at least 
the appearance of such conflict. Hence, 
the participants agreed that for-profit 
HC/HT organizations should not be 
involved in the promotion of donation 
or the interviewing of donors, surrogates 
or next of kin. In addition, regulations 
that minimize commercial conflicts of 
interest in the processing and possibly 
the distribution of cells and tissues were 
considered necessary.
However, there was considerable 
dispute as to how a profit-making ori-
entation might influence processing 
decisions. Although respective evidence 
does not exist, it is conceivable that for-
profit institutions would be more prone 
to process HCs/HTs into the most 
profitable products, thereby imperilling 
equitable access to services (e.g. acellular 
dermis products rather than minimally 
processed skin for burn care).
Meeting discussions yielded the 
following preliminary ethical criteria for 
organizations processing or distribut-
ing cells or tissues with a profit-making 
orientation: donors, surrogates, next of 
kin or legal representatives should be 
informed accordingly; the quality, safety 
and price of cells and tissues should be 
at least comparable to those from not- 
for-profit organizations; and the profit-
making orientation should not compro-
mise equitable access to HC/HT services.
6. Quality and safety of HC/HT 
procurement and processing
All meeting participants considered 
compliance with recent international 
quality and safety standards manda-
tory to guarantee the safety of recipients, 
even if this implies a reduced availabil-
ity of HCs/HTs.17,18 Traceability (that 
is, the capacity to trace cells and tissues 
from the donor to recipients and vice 
versa) and long-term follow-up of living 
donors and recipients of cells and tissues 
are central elements of safety and quality 
management. Many participants envis-
aged for the future the ability to coordi-
nate the traceability of organs and tissues 
in a common surveillance system with 
universal donor identification numbers, 
as many organ donors also donate tissues; 
however, such aspirations were distant for 
participants from resource-poor coun-
tries. The latter urged the international 
community to adopt minimal standards 
for procurement and processing as the 
surest way of helping them to balance 
quality, safety and HC/HT availability.
Quality and safety were consid-
ered a particular concern in for-profit 
autologous cord blood banking, where 
practices are often substandard. In ad-
dition, autologous cord blood banking 
is not an evidence-based practice today, 
but a speculative private investment.4 
Participants therefore agreed that such 
services should only be offered if quality 
standards correspond to those applied 
in allogeneic not-for-profit cord blood 
banks and if parents are fully informed 
about the currently limited clinical ap-
plication of autologous cells.
7. Fair distribution of processed 
cells and tissues
Although the scarcity of HCs/HTs is 
less marked than the scarcity of organs, 
there was broad agreement that HCs/
HTs should be distributed fairly. Par-
ticipants concurred that a fair HC/HT 
distribution could only be achieved 
through the regulated implementation 
of transparent allocation criteria and 
prioritization rules which balance util-
ity and equity considerations in the 
distribution process. While participants 
were committed to medical need as the 
primary consideration in distributing 
HCs/HTs, because donors generally give 
HCs/HTs with the intention to help 
others, they recognized that medical 
need is vague and context-dependent.
Although distribution according to 
medical need would imply prioritizing 
HC/HT use for life-saving purposes over 
life-enhancing or cosmetic purposes, 
participants recognized the practical 
limitations in effectuating such prioriti-
zation. HC/HT processing institutions 
frequently do not know where and 
how their products will be used. Even 
if better oversight was achieved, use 
of small amounts of cells and tissues 
in numerous clinical settings poses a 
clear practical limitation on designing, 
much less implementing, sophisticated 
allocation schemes even in resource-rich 
countries. Some also questioned the 
need for elaborate algorithms because 
most HCs/HTs can be stored, used as 
necessary and imported in case of short-
age; moreover, some medical products 
or devices only contain traces of HCs/
HTs. Nonetheless, all participants agreed 
that allocation rules should be generally 
and explicitly structured; examples in 
this direction already exist.19
Participants also appreciated that 
factors other than medical need can 
influence the distribution of HCs/HTs, 
provided they have been defined in a fair 
process. Regional balance, waiting time, 
the number of waiting patients, and 
reciprocity of services between procure-
ment and processing institutions were 
mentioned (and partially criticized). 
However, all participants rejected dis-
criminatory criteria in the distribution 
process, such as ethnicity and religion.
Some controversy arose about how 
a profit-making orientation affects HC/
HT distribution. Several participants 
were convinced that for-profit institu-
tions should not be involved in distribu-
tion, while others denied the assumed 
conflicts of interest in distribution. 
This disagreement could not be resolved 
because little is currently known about 
HC/HT distribution and the factors 
that influence the availability of, and 
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Table 1. Eight of the central ethical issues in the regulation of human cell (HC) and human tissue (HT) transplantation 
Issue Agreement Disagreement
Consent for HC/HT removal •  No HC/HT removal without consent
• Informed consent for donation from living donors
•  Disclosure of possible limitations to withdrawing 
consent
•  Informed versus presumed consent in deceased 
donation? 
•  Role of the next of kin (“family veto”) in deceased 
donation? 
°  Obligation to inform about possible profit-making, 
international circulation or cosmetic applications?
Confidentiality of donor data •  Confidentiality of donor data (with exceptions)
Unpaid HC/HT donation •  Unpaid donation
•  Removal of financial disincentives for donation
°  Only not-for-profit institutions in donation 
discussions and the promotion of donation 
Fair HC/HT procurement •  Fair criteria for donor identification and selection °  Binding priority of organ over HC/HT recovery?
Stewardship for donated 
HC/HT
•  Obligation to honour and realize donor intent 
•  Option to veto HC/HT use for research or education
•  No discriminatory restrictions of HC/HT use
°  Stewardship, effectiveness, accountability, fair 
pricing, responsiveness to local and/or national 
needs and fair allocation are more important than 
institutional for-profit/not-for-profit structure
°  Option to veto HC/HT use abroad or for cosmetic 
applications? 
Quality and safety 
management
•  Necessity of quality and safety management 
•  Long-term follow-up of donors and recipients
•  Balance between quality, safety and HC/HT 
availability in resource-poor settings?
Fair distribution of processed 
HC/HT
•  Need for allocation criteria and prioritization rules 
despite limited scarcity
°  General priority of HC/HT use for life-saving over 
life-enhancing and cosmetic purposes
°  General priority of local and/or national self-
sufficiency
°  Scope of allocation criteria and prioritization 
rules: institutional, national, subregional?
°  Institutional reciprocity as an allocation criterion?
°  For-profit organizations in HC/HT distribution?
°  General priority of subregional self-sufficiency?
°  International HC/HT circulation to subsidize public 
health care?
Consent for HC/HT 
transplantation
•  No HC/HT transplantation without voluntary and 
informed consent 
°  Obligation to inform recipients about profit-
making and international circulation? 
°  Limits of consent for medically contested uses?
• normative agreement or disagreement was analogous to that for organ transplantation; 
° normative agreement or disagreement was specific for HC/HT transplantation.
equitable access to, HC/HT services, as 
well as about the impact of international 
circulation, legal definitions and regula-
tory requirements.
Whether the scope of allocation 
rules should be institutional, national, 
subregional or international was equally 
controversial. While trade in human cells 
and tissues can help address patients’ 
needs worldwide, it can arguably aggra-
vate global inequities both in donation 
and access to services. It is important to 
recognize that HT/HC organizations – 
in particular those with a profit-making 
orientation – can experience a conflict of 
interest between providing HCs/HTs 
to the donating population and gen-
erating income, inter alia by exporting 
HCs/HTs. To reduce the potential for 
such inequities, participants concluded 
that local or national self-sufficiency 
should have a general priority over in-
ternational solidarity and that HCs/HTs 
should be exported only if exportation 
activities are controlled and transpar-
ent. The University of Pretoria National 
Tissue Bank, for example, will export a 
maximum of 10% of its stock provided 
that the remaining supply is sufficient 
to cover national need for three months. 
The idea of subregional self-sufficiency, 
however, was controversial: some par-
ticipants from resource-poor countries 
argued that the international exportation 
of HCs/HTs after national needs have 
been met is needed to subsidize publicly 
funded national health care.
Finally, meeting participants em-
phasized that achieving equity in access 
to HCs/HTs is not only a matter of fair 
distribution but also of health care in-
frastructure. “Transplant tourism” occurs 
when people in resource-poor countries 
are unable to obtain needed cell or tis-
sue transplants locally. Therefore, to 
achieve self-sufficiency in the provision 
of HC/HT services, national develop-
ment of HC/HT organizations should 
be fostered as far as resources allow.
8. Consent for HC/HT 
transplantation
All meeting participants considered in-
formed and voluntary consent by or on 
behalf of the recipient a necessary require-
ment for HC/HT transplantation. Valid 
consent requires informing the patient 
that a planned intervention contains hu-
man material with specific risks, if any, as 
well as what is known about the interven-
tion’s effectiveness. Yet the extent to which 
recipients should be informed about 
all aspects of HC/HT procurement, 
processing and distribution was conten-
tious. Participants agreed, however, that 
consent alone is not sufficient to validate 
experimental (and medically contested) 
transplants of cells or tissues as “therapy” 
(so-called “miracle cures”).
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Table 2.  Preliminary ethical framework for the regulation of human cell (HC) and 
human tissue (HT) transplantation
Fundamental  
ethical principle
Specification in the context of  
HC/HT transplantation 
Respect for persons •  Informed and voluntary consent for living HC/HT removal 
•  Explicit consent during lifetime or presumed consent for 
deceased HC/HT removal
•  Option to veto future uses of donated HC/HT for research and 
education (and/or cosmetic applications and/or international 
circulation)
•  Stewardship for donated HCs/HTs
•  Informed and voluntary consent for HC/HT transplantation
Non-maleficence •  Minimal quality and safety standards for HC/HT procurement, 
processing and transplantation 
•  Long-term follow-up of living donors and transplant recipients
Justice •  Fair criteria for donor identification and selection
•  Unpaid donation to reduce inequities in donation
•  Fair HC/HT distribution
•  General priority of local and/or national self-sufficiency to 
reduce global inequities in donation of and access to HCs/HTs
Conclusion
The Zurich symposium was the first in-
ternational meeting on the ethical and 
policy issues in human cell and tissue 
transplantation. By selecting, analysing 
and structuring relevant issues, it aimed 
to provide a first step towards the needed 
comprehensive global framework for 
HC/HT transplantation. In the follow-
ing remarks the authors of this paper 
wish to highlight, from their perspective, 
the key insights of the meeting to guide 
future efforts in this direction.
First, the practice of HC/HT trans-
plantation has reached a global dimen-
sion. Activities of national and interna-
tional HC/HT organizations and the 
worldwide circulation of HCs/HTs 
affect the way we practise medicine 
and trade health goods and services 
on a global level. They also entail in-
ternational health risks and have the 
potential to create global inequities in 
access to HCs/HTs. For this reason, 
health authorities and professionals 
from all countries need to develop and 
implement a common normative basis 
for HC/HT transplantation.
Second, activities involving organ 
transplantation are inherently con-
nected with those involving cells and 
tissues. Many ethical and policy issues in 
HC/HT transplantation mirror those 
identified regarding organ transplanta-
tion. At the same time, HC/HT activi-
ties raise distinct questions relating to 
profit-making, cosmetic applications 
and extensive global exchange and trad-
ing. While the regulation of cell and tis-
sue transplantation must accommodate 
these particularities, consistency with 
normative frameworks for organ trans-
plantation remains a prime objective.
Third, the current spectrum of 
practices in HC/HT transplantation is 
wide and difficult to pinpoint. It is hard 
to assess how practices influence na-
tional and international availability of, 
and equitable access to, cells and tissues. 
Research on the actual uses and dis-
tribution of HCs/HTs – in particular 
on the impact of profit-making and 
international circulation, and on appro-
priate allocation schemes – is urgently 
needed.
Fourth, there was considerable 
normative agreement among meeting 
participants (Table 1), which is encour-
aging for future work. Some points of 
agreement may seem trivial considering 
the nuanced debates about the ethics 
and regulation of organ transplantation. 
However, it should be recognized that 
some of these points contrast starkly 
with current practices. For example, at 
present criteria for the identification and 
selection of potential donors are typi-
cally not explicit; for-profit institutions 
are frequently involved in donation dis-
cussions; the ideal of stewardship often 
remains rhetorical; allocation criteria 
and prioritization rules are exceptional; 
and cells and tissues are commonly 
transplanted without full disclosure to 
recipients.
Fifth, general points of normative 
agreement are difficult to specify with 
regard to the large variety of HC/HT 
products. There seems to be a difference 
between transplanting large pieces of in-
tact bone and composite tissues – such 
as entire hands or significant parts of 
faces – and transplanting orthopaedic 
screws that contain traces of bone dust 
to speed healing. The moral significance 
of this intuitive difference and impli-
cations, for example for donor and 
recipient consent and fair distribution, 
requires further inquiry.
Sixth, although the meeting was 
not designed to reach a consensus state-
ment, the authors of this paper think 
that the present areas of normative 
agreement render a preliminary ethical 
framework for HCs/HTs that remains 
to be scrutinized and/or specified (Table 
2). It is based on the three fundamental 
ethical principles of respect for persons, 
non-maleficence and justice, and in our 
view corresponds to the existing norms 
in organ transplantation.13
Certainly, more work is needed in 
this complex area of applied ethics and 
policy-making. It seems clear, however, 
that the only way forward is moving 
towards consistent regulation of, as well 
as common medical, scientific, legal and 
ethical requirements for, human cell, 
tissue and organ transplantation on a 
global basis. The revised WHO Guiding 
principles on human organ transplanta-
tion will be an important step in that 
direction.  ■
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Résumé
Points de vue internationaux sur l’éthique et la réglementation de la transplantation de cellules et de 
tissus humains
La transplantation de cellules et de tissus humains est devenue 
une entreprise d’ampleur mondiale, visant à sauver des vies et 
à améliorer des existences. Bien que les pratiques actuelles 
soulèvent de nombreuses questions éthiques et politiques 
concernant le consentement informé au don, ainsi que la 
rentabilité, la qualité et la sécurité des processus d’acquisition, 
de traitement, de distribution et de circulation internationale 
des cellules et tissus humains. Le présent article rapporte les 
faits marquants récents dans le débat international autour de ces 
questions et notamment l’attention accordée à la transplantation de 
cellules et de tissus dans le cadre du processus actuellement mené 
par l’OMS d’actualisation des « 1991 Guiding principles on human 
organ transplantation ». Plusieurs des organisateurs d’un groupe 
de travail international ayant réuni des participants issus d’horizons 
très divers en juillet 2006 à Zürich résument les domaines d’accord 
et de désaccord sur le plan normatif et identifient les questions 
restant ouvertes concernant les faits et concepts fondamentaux 
pouvant avoir une importance dans la normalisation. Il faut 
traiter ces questions en développant des exigences mondiales 
communes sur les plans médical, scientifique, juridique et éthique 
pour la transplantation de cellules et de tissus humains. Même si 
les recommandations doivent prendre en compte les différentes 
questions éthiques soulevées par les activités faisant appel à des 
cellules et tissus humains, la cohérence avec les cadres normatifs 
de la transplantation d’organes reste un objectif primordial.
Resumen
Perspectivas internacionales sobre la ética y la regulación del trasplante de células y de tejidos humanos
El trasplante de células y tejidos humanos se ha convertido 
en una gran empresa mundial que aspira tanto a salvar vidas 
como a mejorar la calidad de vida. Sin embargo, las prácticas 
actuales suscitan numerosas cuestiones éticas y normativas en 
relación con el consentimiento informado para las donaciones, 
la obtención de lucro, y la calidad y seguridad en materia 
de adquisición, procesamiento, distribución y circulación 
internacional de células y tejidos humanos. En este artículo 
se informa sobre las últimas novedades registradas en el 
debate internacional sobre estas cuestiones, y en particular 
sobre la atención que ha suscitado el trasplante de células y 
tejidos en el proceso seguido actualmente por la OMS para 
actualizar sus Principios rectores sobre el trasplante de órganos 
humanos, de 1991. Varios de los organizadores de un grupo de 
trabajo internacional de interesados directos con muy 
diversas experiencias que se reunió en Zurich en julio de 2006 
resumen aquí las áreas de acuerdo y desacuerdo normativo y 
plantean interrogantes por resolver sobre hechos y conceptos 
fundamentales de eventual trascendencia normativa. Estos temas 
deberán abordarse formulando requisitos médicos, científicos, 
legales y éticos comunes para el trasplante de células y tejidos 
humanos a nivel mundial. Si bien las indicaciones deben tener en 
cuenta los aspectos éticos peculiares que plantean las actividades 
en que se manejan células y tejidos humanos, la coherencia con 
los marcos normativos para el trasplante de órganos sigue siendo 
un objetivo primordial.
ملخص
مناظري دولية بشأن أخالقيات أنشطة زرع الخاليا واألنسجة البرشية، وتنظيمها
التي تجرى  العاملية  لقد أصبح زرع الخاليا واألنسجة البرشية من األنشطة 
ألغراض إنقاذ الحياة وتحسني نوعيتها. إال أن املامرسات القامئة تثري العديد 
باملوافقة  يتصل  ما  يف  بالسياسات  املتعلقة  وتلك  األخالقية،  القضايا  من 
املستنرية عىل التربع، أو تحقيق الربح، أو نوعية ومأمونية عملية رشاء الخاليا 
واألنسجة البرشية ومعالجتها وتوزيعها وتداولها عىل املستوى الدويل. وتقدم 
حول  الدائر  بالجدل  يختص  ما  يف  رات  التطوُّ آخر  عن  تقريراً  الورقة  هذه 
هذه القضايا عىل الصعيد الدويل، والسيَّام االهتامم الذي تلقاه أعامل زرع 
الخاليا واألنسجة ضمن عملية التحديث املستمرة التي تجريها منظمة الصحة 
العاملية عىل املبادئ اإلرشادية املتعلقة بزرع األعضاء البرشية، التي صدرت 
عام 1991. وقد أوجز عدد من منظمي اجتامع فريق العمل الدويل املؤلَّف 
الذين  دة،  املتعدِّ الثقافية  الخلفيات  ذوي  من  ِـّني  املعني الشأن  أصحاب  من 
اجتمعوا يف زيوريخ، يف متوز/ يوليو 2006، أوجه االتفاق واالختالف املعيارية، 
ذات  األساسية  واملفاهيم  بالحقائق  يختص  ما  يف  املعلقة  املسائل  دوا  وحدَّ
الداللة املعيارية املحتملة. وينبغي بحث هذه القضايا من خالل وضع قواعد 
طبية وعلمية وقانونية وأخالقية عامة ألنشطة زرع الخاليا واألنسجة البرشية 
للقضايا  اإلرشادات  استيعاب  حتمية  من  الرغم  وعىل  عاملي.  أساس  عىل 
بالخاليا  الصلة  ذات  األنشطة  بسبب  أثريت  التي  املعامل  الواضحة  األخالقية 
واألنسجة البرشية، فإن متشيها مع األُُطر املعيارية لعملية زرع األعضاء يظل 
هدفاً أساسياً.
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